Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$106.44 USD

106.44
1,208,547

-1.65 (-1.53%)

Updated Jul 30, 2024 04:00 PM ET

After-Market: $106.33 -0.11 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Masimo Gets FDA Nod for Rad-97, Enables Healthcare at Home

Masimo (MASI) states that with its inherent touchscreen interface, Rad-97 is user-friendly for clinicians and non-clinicians and can be easily tailored to cater to the needs of home users.

    Cogentix (CGNT) Stock Near 52-Week High: More Room to Run?

    Cogentix Medical (CGNT) stock continues to hover around the 52-week high mark reached on Dec 27, courtesy of its new strategies.

      Robust Pipeline Aids Edwards Lifesciences, Rising Costs Ail

      Edwards Lifesciences' (EW) pipeline building to fortify foothold across all operating businesses bodes well. Also, the TAVR adoption rate across Japan and the European countries is impressive.

        Align Rides on Balanced Segmental Growth Amid Stiff Contest

        Align (ALGN) gains from balanced sales growth across all its channels of late, primarily on high InvisAlign Technology case volumes.

          Here's Why You Should Invest in Masimo (MASI) Right Now

          Masimo (MASI) rides high on its solid guidance. The company's recent FDA approval is also encouraging.

            The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies

            The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies

              5 MedTech Stocks to Beat Tax Hazards With Positive Returns

              Trump's tax reform policies promise to cut corporate taxes. However, the future of the U.S. MedTech industry depends on the much-awaited decision on the 2.3% medical device tax.

                Here's Why You Should Invest in Masimo (MASI) Right Now

                Masimo (MASI) continues to grow on innovation and product launches.

                  Masimo (MASI) Beats on Q3 Earnings and Revenues, Raises View

                  Masimo (MASI) raises fiscal 2017 guidance. The year-over-year increase in both revenues and earnings encourages.

                    Masimo (MASI) Launches Trace Data and Reporting Tool in US

                    Masimo's (MASI) launch of Trace in the United States will aid the company in capturing the growing patient data visualization market.

                      AmerisourceBergen's PharMEDium Slows Down, Competition Rife

                      AmerisourceBergen'S (ABC) growth story is expected to be stunted by tepid performance at PharMEDium. Also steep competition is a cause of concern.

                        Amedisys' Arm Buys Intercity Home Care, Boosts U.S. Base

                        Amedisys' (AMED) encouraging efforts put the Personal Care business on growth track. This segment lives up to a strong performance with the integration of several recent tuck-in acquisitions.

                          Abbott to Gain from Alere's Takeover Due for Oct 3 Closure

                          Alere's acquisition would help Abbott (ABT) explore new channels and geographies, including forays into fast growing outlets like doctors' offices, clinics, pharmacies and at-home testing.

                            Masimo RAS-45 Full-Market Release to Boost Respiratory Care

                            Masimo Corporation's (MASI) newly launched RAS-45, a single use adhesive respiration sensor would strengthen the company's foothold in the growing global respiratory care market.

                              Here's Why Investors Should Buy Masimo (MASI) Right Now

                              Masimo (MASI) announced 510(k) clearance and full-market release of its proprietary Rad-97 Pulse CO-Oximeter earlier this month.

                                The Zacks Analyst Blog Highlights: Cardinal Health, Penumbra, STAAR Surgical, Masimo and Smith & Nephew

                                The Zacks Analyst Blog Highlights: Cardinal Health, Penumbra, STAAR Surgical, Masimo and Smith & Nephew

                                  Top MedTech Stocks Safe from Graham-Cassidy Repeal Bill

                                  The investment climate for medical device majors has become increasingly volatile due to political potshots in Capitol Hill, for and against Obamacare.

                                    Republicans Take Last Shot at Obamacare: 5 MedTech Stocks to Buy

                                    The fate of Obamacare will be decided on Sep. 30. No matter what the future holds, the day will provide investors a clear picture of where the MedTech industry is headed.

                                      Masimo (MASI) Launches Rad-97 CO-Oximeter Post FDA Clearance

                                      Masimo's (MASI) newly-launched Rad-97 Pulse CO-Oximeter will strengthen the company's presence in the Advanced Monitoring Technologies space.

                                        5 Discounted MedTech Stocks for a Healthy Portfolio

                                        In view of the current political scenario and banking on favorable metrics, these five MedTech stocks stand out as the most suitable value picks.

                                          Why Is Masimo (MASI) Down 1.5% Since the Last Earnings Report?

                                          Masimo (MASI) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                            Ride Out MedTech Volatility With These 3 Ultra-Safe Stocks

                                            In view of the current political scenario and banking on favorable metrics, these three low-beta MedTech stocks stand out as the most suitable value picks.

                                              3 Excellent Value Picks as Political Chaos Grips MedTech

                                              In view of the current political scenario and banking on favorable metrics, these three MedTech stocks stand out as the most suitable value picks.

                                                Zacks.com featured highlights: CBRE Group, East West Bancorp, Hasbro, Canadian Pacific Railway and Masimo

                                                Zacks.com featured highlights: CBRE Group, East West Bancorp, Hasbro, Canadian Pacific Railway and Masimo

                                                  5 GARP Stocks to Buy for Marvelous Returns

                                                  GARP helps an investor gain exposure to stocks that are undervalued and have impressive prospects.